{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"461"}]}],"title":"Any non-SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"200"}]}],"title":"Any SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"463"}],"units":"Participants"}],"description":"An adverse event is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE. Adverse events which were not serious were considered as Non-serious adverse events.","groups":[{"description":"Participants received Niraparib (300 milligram \\[mg\\], taken as 3 capsules of 100 mg once daily \\[QD\\]) orally beginning on Day 1 of every cycle (28 days) until treatment discontinuation.","id":"OG000","title":"Niraparib 300 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population was comprised of all participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to a maximum of 71.56 months","title":"Number of Participants With Any Non-serious Adverse Event (Non-SAE) and Any Serious Adverse Event (SAE)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}